BACKGROUND: The Primary Immune Deficiency Treatment Consortium was formed to analyze the results of hematopoietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immunodeficiencies. Factors associated with a good transplantation outcome need to be identified in order to design safer and more effective curative therapy, particularly for children with SCID diagnosed at birth. METHODS: We collected data retrospectively from 240 infants with SCID who had received transplants at 25 centers during a 10-year period (2000 through 2009). RESULTS: Survival at 5 years, freedom from immunoglobulin substitution, and CD3+ T-cell and IgA recovery were more likely among recipients of grafts from matched sibling donors than among recipients of grafts from alternative donors. However, the survival rate was high regardless of donor type among infants who received transplants at 3.5 months of age or younger (94%) and among older infants without prior infection (90%) or with infection that had resolved (82%). Among actively infected infants without a matched sibling donor, survival was best among recipients of haploidentical T-cell-depleted transplants in the absence of any pretransplantation conditioning. Among survivors, reduced-intensity or myeloablative pretransplantation conditioning was associated with an increased likelihood of a CD3+ T-cell count of more than 1000 per cubic millimeter, freedom from immunoglobulin substitution, and IgA recovery but did not significantly affect CD4+ T-cell recovery or recovery of phytohemagglutinin-induced T-cell proliferation. The genetic subtype of SCID affected the quality of CD3+ T-cell recovery but not survival. CONCLUSIONS: Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection. All available graft sources are expected to lead to excellent survival among asymptomatic infants. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
BACKGROUND: The Primary Immune Deficiency Treatment Consortium was formed to analyze the results of hematopoietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immunodeficiencies. Factors associated with a good transplantation outcome need to be identified in order to design safer and more effective curative therapy, particularly for children with SCID diagnosed at birth. METHODS: We collected data retrospectively from 240 infants with SCID who had received transplants at 25 centers during a 10-year period (2000 through 2009). RESULTS: Survival at 5 years, freedom from immunoglobulin substitution, and CD3+ T-cell and IgA recovery were more likely among recipients of grafts from matched sibling donors than among recipients of grafts from alternative donors. However, the survival rate was high regardless of donor type among infants who received transplants at 3.5 months of age or younger (94%) and among older infants without prior infection (90%) or with infection that had resolved (82%). Among actively infected infants without a matched sibling donor, survival was best among recipients of haploidentical T-cell-depleted transplants in the absence of any pretransplantation conditioning. Among survivors, reduced-intensity or myeloablative pretransplantation conditioning was associated with an increased likelihood of a CD3+ T-cell count of more than 1000 per cubic millimeter, freedom from immunoglobulin substitution, and IgA recovery but did not significantly affect CD4+ T-cell recovery or recovery of phytohemagglutinin-induced T-cell proliferation. The genetic subtype of SCID affected the quality of CD3+ T-cell recovery but not survival. CONCLUSIONS: Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection. All available graft sources are expected to lead to excellent survival among asymptomatic infants. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
Authors: Lucinda Brown; Jinhua Xu-Bayford; Zoe Allwood; Mary Slatter; Andrew Cant; E Graham Davies; Paul Veys; Andrew R Gennery; H Bobby Gaspar Journal: Blood Date: 2011-01-27 Impact factor: 22.113
Authors: Juliana F Fernandes; Vanderson Rocha; Myriam Labopin; Benedicte Neven; Despina Moshous; Andrew R Gennery; Wilhelm Friedrich; Fulvio Porta; Cristina Diaz de Heredia; Donna Wall; Yves Bertrand; Paul Veys; Mary Slatter; Ansgar Schulz; Ka Wah Chan; Michael Grimley; Mouhab Ayas; Tayfun Gungor; Wolfram Ebell; Carmem Bonfim; Krzysztof Kalwak; Pierre Taupin; Stéphane Blanche; H Bobby Gaspar; Paul Landais; Alain Fischer; Eliane Gluckman; Marina Cavazzana-Calvo Journal: Blood Date: 2012-02-03 Impact factor: 22.113
Authors: A Borgmann-Staudt; R Rendtorff; S Reinmuth; C Hohmann; T Keil; F R Schuster; W Holter; K Ehlert; P Keslova; A Lawitschka; A Jarisch; G Strauss Journal: Bone Marrow Transplant Date: 2011-04-11 Impact factor: 5.483
Authors: Antonia Kwan; Joseph A Church; Morton J Cowan; Rajni Agarwal; Neena Kapoor; Donald B Kohn; David B Lewis; Sean A McGhee; Theodore B Moore; E Richard Stiehm; Matthew Porteus; Constantino P Aznar; Robert Currier; Fred Lorey; Jennifer M Puck Journal: J Allergy Clin Immunol Date: 2013-07 Impact factor: 10.793
Authors: Penny Titman; Elizabeth Pink; Emily Skucek; Katherine O'Hanlon; Tim J Cole; Jane Gaspar; Jinhua Xu-Bayford; Alison Jones; Adrian J Thrasher; E Graham Davies; Paul A Veys; H Bobby Gaspar Journal: Blood Date: 2008-07-21 Impact factor: 22.113
Authors: F Porta; S Cavagnini; L Imberti; A Sottini; F Bolda; A Beghin; A Caruso; A Lanfranchi Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Alexandra M Miggelbrink; Brent R Logan; Rebecca H Buckley; Roberta E Parrott; Christopher C Dvorak; Neena Kapoor; Hisham Abdel-Azim; Susan E Prockop; David Shyr; Hélène Decaluwe; Imelda C Hanson; Alfred Gillio; Blachy J Dávila Saldaña; Hermann Eibel; Gregory Hopkins; Jolan E Walter; Jennifer S Whangbo; Donald B Kohn; Jennifer M Puck; Morton J Cowan; Linda M Griffith; Elie Haddad; Richard J O'Reilly; Luigi D Notarangelo; Sung-Yun Pai Journal: Blood Date: 2018-05-04 Impact factor: 22.113
Authors: Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem Journal: Blood Adv Date: 2018-05-08
Authors: C C Dvorak; K Patel; J M Puck; J Wahlstrom; M J Dorsey; R Adams; J Facchino; M J Cowan Journal: Bone Marrow Transplant Date: 2017-04-24 Impact factor: 5.483
Authors: M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman Journal: J Allergy Clin Immunol Date: 2016-09-30 Impact factor: 10.793
Authors: Asbjørg Stray-Pedersen; Hanne Sørmo Sorte; Pubudu Samarakoon; Tomasz Gambin; Ivan K Chinn; Zeynep H Coban Akdemir; Hans Christian Erichsen; Lisa R Forbes; Shen Gu; Bo Yuan; Shalini N Jhangiani; Donna M Muzny; Olaug Kristin Rødningen; Ying Sheng; Sarah K Nicholas; Lenora M Noroski; Filiz O Seeborg; Carla M Davis; Debra L Canter; Emily M Mace; Timothy J Vece; Carl E Allen; Harshal A Abhyankar; Philip M Boone; Christine R Beck; Wojciech Wiszniewski; Børre Fevang; Pål Aukrust; Geir E Tjønnfjord; Tobias Gedde-Dahl; Henrik Hjorth-Hansen; Ingunn Dybedal; Ingvild Nordøy; Silje F Jørgensen; Tore G Abrahamsen; Torstein Øverland; Anne Grete Bechensteen; Vegard Skogen; Liv T N Osnes; Mari Ann Kulseth; Trine E Prescott; Cecilie F Rustad; Ketil R Heimdal; John W Belmont; Nicholas L Rider; Javier Chinen; Tram N Cao; Eric A Smith; Maria Soledad Caldirola; Liliana Bezrodnik; Saul Oswaldo Lugo Reyes; Francisco J Espinosa Rosales; Nina Denisse Guerrero-Cursaru; Luis Alberto Pedroza; Cecilia M Poli; Jose L Franco; Claudia M Trujillo Vargas; Juan Carlos Aldave Becerra; Nicola Wright; Thomas B Issekutz; Andrew C Issekutz; Jordan Abbott; Jason W Caldwell; Diana K Bayer; Alice Y Chan; Alessandro Aiuti; Caterina Cancrini; Eva Holmberg; Christina West; Magnus Burstedt; Ender Karaca; Gözde Yesil; Hasibe Artac; Yavuz Bayram; Mehmed Musa Atik; Mohammad K Eldomery; Mohammad S Ehlayel; Stephen Jolles; Berit Flatø; Alison A Bertuch; I Celine Hanson; Victor W Zhang; Lee-Jun Wong; Jianhong Hu; Magdalena Walkiewicz; Yaping Yang; Christine M Eng; Eric Boerwinkle; Richard A Gibbs; William T Shearer; Robert Lyle; Jordan S Orange; James R Lupski Journal: J Allergy Clin Immunol Date: 2016-07-16 Impact factor: 10.793